Trials / Completed
CompletedNCT03219632
Fimasartan on Hypertensive Cardiac Disease With Left Ventricular Hypertrophy Estimated by ECG
Angiotensin Blocking Effect of Fimasartan on Hypertensive Cardiac Disease With Left Ventricular Hypertrophy Estimated by ECG: a Prospective, Multicenter, Observational Registry
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 72 (actual)
- Sponsor
- Seoul National University Bundang Hospital · Academic / Other
- Sex
- All
- Age
- 20 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Assess the efficacy of fimasartan on left ventricular hypertrophy in hypertensive patients
Detailed description
Patients who were diagnosed with left ventricular hypertrophy (LVH) by ECG at the start of the study are followed up at 3-month intervals for 1 year. Increase Fimasartan if blood pressure is not controlled.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fimasartan | Fimasartan is a non-peptide angiotensin II receptor antagonist (ARB) used for the treatment of hypertension and heart failure. |
Timeline
- Start date
- 2012-06-05
- Primary completion
- 2017-04-30
- Completion
- 2017-05-30
- First posted
- 2017-07-17
- Last updated
- 2017-07-17
Source: ClinicalTrials.gov record NCT03219632. Inclusion in this directory is not an endorsement.